Seeking Alpha

Seeking Alpha Portfolio App for iPad

LATEST ARTICLES

ARTICLES | NEWS | TRANSCRIPTS

Acadia: Multiple Data Points Suggest Further Upside In The Stock
Josh Hutheson • ACAD • Fri, May 24, 11:00 ET
Actavis Buys Warner Chilcott, Upside Seems Limited
New Low Observer • WCRX, ACT • Fri, May 24, 10:51 ET
2 Healthcare Companies With Recent Intensive Insider Buying
Markus Aarnio • AMBI, OFIX • Fri, May 24, 08:38 ET
United Therapeutics: A Growth Stock With Good Products And A Promising Pipeline
StockRiters • UTHR • Fri, May 24, 08:28 ET
A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013
Tech Guru • AMAG, DVAX, KERX • Fri, May 24, 08:17 ET
Amarin Stays Rangebound, Prescriptions Stagnate
Brian L. Wilson • AMRN • Fri, May 24, 06:17 ET
Vivus Heats Up, Shorts Discouraged On Possible Bidding War
Brian L. Wilson • VVUS • Fri, May 24, 05:41 ET
Dividend Growth Gem Medtronic Is A Cash Cow
Valuentum • MDT • Fri, May 24, 04:39 ET
Amgen: Financial Analysis And Valuation
Shankar N • AMGN • Fri, May 24, 03:26 ET
Arena - Good Sales, Bad Sales, Long And Short
Spencer Osborne • OREX, VVUS, ARNA • Fri, May 24, 02:53 ET
Actavis To Increase Operational Synergies By Acquiring Warner
Alpha Hunter • WCRX, ACT • Fri, May 24, 02:36 ET
Pfizer Has Potential To Grow Despite Decreasing Sales
Alpha Hunter • PFE • Fri, May 24, 02:23 ET
First Manhattan Still Playing Hardball With Vivus
Spencer Osborne • ARNA, VVUS • Fri, May 24, 00:06 ET
Peregrine Pharmaceuticals, The Little Biotech With The Golden Goose Of Immunotherapy
Chris Lacoursiere • PPHM • Thu, May 23, 17:49 ET
Follow The 'Smart Money' And Buy Johnson & Johnson In The Next Pullback
Hawkinvest • ABBV, ABT, SPY • Thu, May 23, 15:48 ET
Why Merck Shares Are Cheap And Could Rise To $60
Trade In Mexico • MRK • Thu, May 23, 15:41 ET
Arena Is Still A Great Short
EnhydrisPECorp • ESALY.PK, ARNA • Thu, May 23, 15:08 ET
Expanding Use Of Alexion's Specialty Drug Soliris Offers Upside
Todd Campbell • ALXN • Thu, May 23, 13:23 ET
Arena Buyout More 'Highly Probable' Than MannKind
Chris_Roberts • MNKD, ARNA • Thu, May 23, 13:20 ET
Another Look At Marketing Vs. R&D In Pharma
Derek Lowe • PFE • Thu, May 23, 11:29 ET
Thoratec, A Bio Stock With Good Potential And Products
StockRiters • THOR • Thu, May 23, 08:48 ET
Abbott Laboratories: Undervalued Potential
Fundamental Analyst • ABBV, ABT • Thu, May 23, 08:48 ET
Zalicus Awaiting Data On Potential New Pain Medication
Len Zehr • ZLCS • Thu, May 23, 08:19 ET
MannKind's Afrezza And The Oramed Threat
Cory Renauer • ORMP, MNKD • Thu, May 23, 08:10 ET
Johnson & Johnson: At The Crossroads - Part IV - One Road To Higher Profit Growth Rates
Robert Honeywill • BSX, SSH, STJ • Thu, May 23, 06:30 ET
Intuitive Surgical: Years Of Super Growth Ahead
Fundamental Investor • ISRG • Thu, May 23, 06:30 ET
Will Arena's Belviq Be The Next Anti-Obesity Drug To Make The Cover Of Time Magazine?
Reasonable Risk • VVUS, ESALY.PK, ARNA • Thu, May 23, 02:49 ET
Why Doctors Can Prescribe Arena's Belviq For Off Label Uses Without Worrying About Legal Liability
Jacob Smith • ARNA • Wed, May 22, 23:06 ET
Medtronic's Defibrillator Sales Show A Pulse With Encouraging Results
Trefis • MDT • Wed, May 22, 19:21 ET
Bull of the Day: Santarus
Zacks Investment Research • SNTS • Wed, May 22, 18:03 ET
The Retire Young Portfolio: Time To Add A High-Growth Medicine Company
Jacob Steinberg • SNTS • Wed, May 22, 16:10 ET
Regeneron Shareholders Watching Optina Trial Closely
Tom Welch • AMPE, NVS, REGN • Wed, May 22, 15:56 ET
Sequenom: Plenty Of Room To Run
Ravi Jain • SQNM • Wed, May 22, 15:54 ET
Rockwell Steadies Itself For A Phase III Run-Up
Sam Quirke • RMTI • Wed, May 22, 15:09 ET
Ariad's Cancer Drug Iclusig Extends The Gleevec Magic
Peter Geschek • NVS, ARIA • Wed, May 22, 13:20 ET
Why Momenta Offers A Unique Opportunity In The Pharmaceutical Industry
Jon Crowley • BAX, NVS, TEVA • Wed, May 22, 12:56 ET
These 2 Patents Could Mean Everything Or Nothing
Quoth the Raven • CLSN, AMRN • Wed, May 22, 11:29 ET
Nanospheres High Margin Pathogen Identification System Shows Promise
Healthcare Specialist • NSPH • Wed, May 22, 09:45 ET
Dendreon Analysts Getting Very Skeptical
Bill Maurer • DNDN • Wed, May 22, 08:49 ET
Merck's Novel Immunotherapy Drug Receives 'Breakthrough Therapy Designation'
The Swiss Trader • MRK • Wed, May 22, 08:34 ET
The 'New' Celsion Could Be Worth $4 A Share
Quoth the Raven • CLSN • Wed, May 22, 08:28 ET
Neuralstem Phase I Results Encourage Market, Stimulate Buying
Brian L. Wilson • CUR • Wed, May 22, 07:33 ET
Prolor Biotech Buyout: Is The Opko Bear Case Now Dead?
Daniel Lauchheimer • OPK, PBTH • Wed, May 22, 06:10 ET
Hodgkin Lymphoma: The Top Secret Strategy Of Seattle Genetics Revealed
Michael Webb • SGEN • Wed, May 22, 06:02 ET
Pricing A Highly Probable Takeover Of MannKind
George Rho • LLY, MRK, NVO • Wed, May 22, 05:28 ET
Cumberland Pharma On The Right Track... But Moving Slowly
Vince Martin • CPIX • Wed, May 22, 04:38 ET
Arena Pharmaceuticals - Out To Launch Or Out To Lunch?
Spencer Osborne • VVUS, ARNA • Wed, May 22, 03:19 ET
Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide
PropThink • IRWD, FRX, SCMP • Tue, May 21, 13:41 ET
Bull Of The Day: Heartware
Zacks Investment Research • HTWR • Tue, May 21, 12:48 ET
Thermo Fisher A Decent Long-Term Opportunity
Fundamental Analyst • A, DGX, LIFE • Tue, May 21, 11:35 ET

First Page
Previous Page
1 - 50 of 14831
Next Page
Last Page